Matthew Heeney

Matthew Heeney, MD

Director, Clinical Hematology; Director, Sickle Cell Program

Assistant Professor of Pediatrics, Harvard Medical School

  • Contact: 617-355-7700

  • Fax: 617-730-0641

Medical Services

Specialties

  • Sickle Cell Disease
  • Iron Deficiency
  • Hemoglobinopathies
  • Hematology Oncology
  • Sideroblastic Anemia

Departments

  • Hematology / Oncology
  • Medicine

Programs

  • Hematology / Oncology
  • Hematology / Oncology
  • Rare Anemias and Iron Disorders Program
To schedule an appointment: Call 617-355-7700 or Request an Appointment

Experience and Education

Education

Undergraduate

Trinity College, University of Toronto, 1992

Toronto, Canada

Medical School

University of Calgary, 1995

Calgary, Canada

Fellowship, Pediatric Hematology/Oncology

Duke University Medical Center, 1999-2002

Durham, NC

Residency

Montreal Children's Hospital, McGill University, 1995-1999

Montreal, Canada

Certifications

  • Pediatrics, Pediatric Hematology/Oncology

Professional History

Matthew Heeney, MD is Board Certified in Pediatrics and Pediatric Hematology/Oncology. He is the Associate Chief for Hematology in the Division of Hematology/Oncology and the Director of the Sickle Cell Program in the Dana-Farber Boston Children’s Cancer and Blood Disorders Center (DFBCCBD). Dr. Heeney’s research Interests are focused on sickle cell disease and congenital disorders of iron metabolism. The goals of Dr. Heeney's research work include: to improve the understanding of the pathophysiology and treatment of sickle cell anemia through clinical investigation and to elucidate the genetic basis of iron homeostasis and its role in human disease.
Dr. Heeney has been the Boston Children's Hospital Site Investigator for several clinical trial consortia including the former Sickle Cell Disease Research Network (SCDCRN), and Comprehensive Sickle Cell Center (CSCC). He is also the Site Investigator for the multicenter SWiTCH and TWiTCH trials which are exploring the use of Hydroxyurea as an alternative to chronic transfusion for stroke prevention in sickle cell disease. He is also involved in early phase trials of prasugrel and regadenoson in sickle cell disease. Dr. Heeney also conducts translational research in inherited disorders of iron homeostasis in humans. In particular he is interested in investigating the genetic basis inherited disorders of iron deficiency, sideroblastic anemia and iron overload.
Dr. Heeney is an Assistant Professor of Pediatrics at Harvard Medical School and is committed to medical education as the Co-Director of the Hematology course for 2nd year HMS students. He is a frequent lecturer on hematology topics in HMS sponsored continuing medical education and BCH training programs.. Dr. Heeney received his MD at the University of Calgary, Alberta, completed his pediatrics residency at Montreal Children's Hospital, McGill University, and a pediatric hematology/oncology fellowship at Duke University.

Research

Dr. Heeney conducts clinical research focused on sickle cell disorders and their treatment. He has been the Children's Hospital Boston Principal Investigator (PI) for the Boston Comprehensive Sickle Cell Center (CSCC)and the Boston Sickle Cell Disease Research Network (SCDCRN). He is the CHB PI and for the multicenter SWiTCH and TWiTCH trials which are exploring the use of Hydroxyurea as an alternative to chronic transfusion for stroke prevention. Dr. Heeney also conducts translational research in inherited disorders of iron homeostasis in humans. In particular he is interested in investigating the genetic basis inherited disorders of iron deficiency, sideroblastic anemia and iron overload. Goals of Dr. Heeney's work include: to improve the understanding of the pathophysiology and treatment of sickle cell anemia through multicenter clinical trials and to elucidate the genetic basis of iron homeostasis and its role in human disease.

Publications

Publications powered by Harvard Catalyst Profiles
  1. Heeney MM, Hoppe CC, Rees DC. Prasugrel for Sickle Cell Vaso-Occlusive Events. N Engl J Med. 2016 Jul 14; 375(2):185-6.
  2. Tubman VN, Marshall R, Jallah W, Guo D, Ma C, Ohene-Frempong K, London WB, Heeney MM. Newborn Screening for Sickle Cell Disease in Liberia: A Pilot Study. Pediatr Blood Cancer. 2016 Apr; 63(4):671-6.
  3. Heeney MM, Hoppe CC, Abboud MR, Inusa B, Kanter J, Ogutu B, Brown PB, Heath LE, Jakubowski JA, Zhou C, Zamoryakhin D, Agbenyega T, Colombatti R, Hassab HM, Nduba VN, Oyieko JN, Robitaille N, Segbefia CI, Rees DC. A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events. N Engl J Med. 2016 Feb 18; 374(7):625-35.
  4. Ware RE, Davis BR, Schultz WH, Brown RC, Aygun B, Sarnaik S, Odame I, Fuh B, George A, Owen W, Luchtman-Jones L, Rogers ZR, Hilliard L, Gauger C, Piccone C, Lee MT, Kwiatkowski JL, Jackson S, Miller ST, Roberts C, Heeney MM, Kalfa TA, Nelson S, Imran H, Nottage K, Alvarez O, Rhodes M, Thompson AA, Rothman JA, Helton KJ, Roberts D, Coleman J, Bonner MJ, Kutlar A, Patel N, Wood J, Piller L, Wei P, Luden J, Mortier NA, Stuber SE, Luban NL, Cohen AR, Pressel S, Adams RJ. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2016 Feb 13; 387(10019):661-70.
  5. Englum BR, Rothman J, Leonard S, Reiter A, Thornburg C, Brindle M, Wright N, Heeney MM, Jason Smithers C, Brown RL, Kalfa T, Langer JC, Cada M, Oldham KT, Scott JP, St Peter SD, Sharma M, Davidoff AM, Nottage K, Bernabe K, Wilson DB, Dutta S, Glader B, Crary SE, Dassinger MS, Dunbar L, Islam S, Kumar M, Rescorla F, Bruch S, Campbell A, Austin M, Sidonio R, Blakely ML, Rice HE. Hematologic outcomes after total splenectomy and partial splenectomy for congenital hemolytic anemia. J Pediatr Surg. 2016 Jan; 51(1):122-7.
  6. Schmitz-Abe K, Ciesielski SJ, Schmidt PJ, Campagna DR, Rahimov F, Schilke BA, Cuijpers M, Rieneck K, Lausen B, Linenberger ML, Sendamarai AK, Guo C, Hofmann I, Newburger PE, Matthews D, Shimamura A, Snijders PJ, Towne MC, Niemeyer CM, Watson HG, Dziegiel MH, Heeney MM, May A, Bottomley SS, Swinkels DW, Markianos K, Craig EA, Fleming MD. Congenital sideroblastic anemia due to mutations in the mitochondrial HSP70 homologue HSPA9. Blood. 2015 Dec 17; 126(25):2734-8.
  7. Hoppe CC, Styles L, Heath LE, Zhou C, Jakubowski JA, Winters KJ, Brown PB, Rees DC, Heeney MM. Design of the DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) trial: A global Phase 3 double-blind, randomized, placebo-controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dose titration strategy. Pediatr Blood Cancer. 2016 Feb; 63(2):299-305.
  8. Wood JC, Pressel S, Rogers ZR, Odame I, Kwiatkowski JL, Lee MT, Owen WC, Cohen AR, St Pierre T, Heeney MM, Schultz WH, Davis BR, Ware RE. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. Am J Hematol. 2015 Sep; 90(9):806-10.
  9. Aygun B, Mortier NA, Kesler K, Lockhart A, Schultz WH, Cohen AR, Alvarez O, Rogers ZR, Kwiatkowski JL, Miller ST, Sylvestre P, Iyer R, Lane PA, Ware RE. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. Br J Haematol. 2015 Apr; 169(2):262-6.
  10. Styles L, Heiselman D, Heath LE, Moser BA, Small DS, Jakubowski JA, Zhou C, Redding-Lallinger R, Heeney MM, Quinn CT, Rana SR, Kanter J, Winters KJ. Prasugrel in children with sickle cell disease: pharmacokinetic and pharmacodynamic data from an open-label, adaptive-design, dose-ranging study. J Pediatr Hematol Oncol. 2015 Jan; 37(1):1-9.
  11. Show all
  12. Rice HE, Englum BR, Rothman J, Leonard S, Reiter A, Thornburg C, Brindle M, Wright N, Heeney MM, Smithers C, Brown RL, Kalfa T, Langer JC, Cada M, Oldham KT, Scott JP, St Peter S, Sharma M, Davidoff AM, Nottage K, Bernabe K, Wilson DB, Dutta S, Glader B, Crary SE, Dassinger MS, Dunbar L, Islam S, Kumar M, Rescorla F, Bruch S, Campbell A, Austin M, Sidonio R, Blakely ML. Clinical outcomes of splenectomy in children: report of the splenectomy in congenital hemolytic anemia registry. Am J Hematol. 2015 Mar; 90(3):187-92.
  13. Heeney MM. Iron clad: iron homeostasis and the diagnosis of hereditary iron overload. Hematology Am Soc Hematol Educ Program. 2014 Dec 5; 2014(1):202-9.
  14. Chakraborty PK, Schmitz-Abe K, Kennedy EK, Mamady H, Naas T, Durie D, Campagna DR, Lau A, Sendamarai AK, Wiseman DH, May A, Jolles S, Connor P, Powell C, Heeney MM, Giardina PJ, Klaassen RJ, Kannengiesser C, Thuret I, Thompson AA, Marques L, Hughes S, Bonney DK, Bottomley SS, Wynn RF, Laxer RM, Minniti CP, Moppett J, Bordon V, Geraghty M, Joyce PB, Markianos K, Rudner AD, Holcik M, Fleming MD. Mutations in TRNT1 cause congenital sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD). Blood. 2014 Oct 30; 124(18):2867-71.
  15. Heeney MM, Cohen AR. Iron disorders. Hematol Oncol Clin North Am. 2014 Aug; 28(4):ix-x.
  16. Helton KJ, Adams RJ, Kesler KL, Lockhart A, Aygun B, Driscoll C, Heeney MM, Jackson SM, Krishnamurti L, Miller ST, Sarnaik SA, Schultz WH, Ware RE. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood. 2014 Aug 7; 124(6):891-8.
  17. Heeney MM, Finberg KE. Iron-refractory iron deficiency anemia (IRIDA). Hematol Oncol Clin North Am. 2014 Aug; 28(4):637-52, v.
  18. Campagna DR, de Bie CI, Schmitz-Abe K, Sweeney M, Sendamarai AK, Schmidt PJ, Heeney MM, Yntema HG, Kannengiesser C, Grandchamp B, Niemeyer CM, Knoers NV, Swart S, Marron G, van Wijk R, Raymakers RA, May A, Markianos K, Bottomley SS, Swinkels DW, Fleming MD. X-linked sideroblastic anemia due to ALAS2 intron 1 enhancer element GATA-binding site mutations. Am J Hematol. 2014 Mar; 89(3):315-9.
  19. Ogunlesi F, Heeney MM, Koumbourlis AC. Systemic corticosteroids in acute chest syndrome: friend or foe? Paediatr Respir Rev. 2014 Mar; 15(1):24-7.
  20. Alvarez O, Yovetich NA, Scott JP, Owen W, Miller ST, Schultz W, Lockhart A, Aygun B, Flanagan J, Bonner M, Mueller BU, Ware RE. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. Am J Hematol. 2013 Nov; 88(11):932-8.
  21. Baskin MN, Goh XL, Heeney MM, Harper MB. Bacteremia risk and outpatient management of febrile patients with sickle cell disease. Pediatrics. 2013 Jun; 131(6):1035-41.
  22. Wiseman DH, May A, Jolles S, Connor P, Powell C, Heeney MM, Giardina PJ, Klaassen RJ, Chakraborty P, Geraghty MT, Major-Cook N, Kannengiesser C, Thuret I, Thompson AA, Marques L, Hughes S, Bonney DK, Bottomley SS, Fleming MD, Wynn RF. A novel syndrome of congenital sideroblastic anemia, B-cell immunodeficiency, periodic fevers, and developmental delay (SIFD). Blood. 2013 Jul 4; 122(1):112-23.
  23. Frelinger AL, Jakubowski JA, Brooks JK, Carmichael SL, Berny-Lang MA, Barnard MR, Heeney MM, Michelson AD. Platelet activation and inhibition in sickle cell disease (pains) study. Platelets. 2014; 25(1):27-35.
  24. Chawla A, Sprinz PG, Welch J, Heeney M, Usmani N, Pashankar F, Kavanagh P. Weight status of children with sickle cell disease. Pediatrics. 2013 Apr; 131(4):e1168-73.
  25. Strouse JJ, Heeney MM. Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children. Pediatr Blood Cancer. 2012 Aug; 59(2):365-71.
  26. Ware RE, Helms RW. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood. 2012 Apr 26; 119(17):3925-32.
  27. McCarville MB, Rogers ZR, Sarnaik S, Scott P, Aygun B, Hilliard L, Lee MT, Kalinyak K, Owen W, Garro J, Schultz W, Yovetich N, Ware RE. Effects of chronic transfusions on abdominal sonographic abnormalities in children with sickle cell anemia. J Pediatr. 2012 Feb; 160(2):281-285.e1.
  28. Stewart AK, Shmukler BE, Vandorpe DH, Rivera A, Heneghan JF, Li X, Hsu A, Karpatkin M, O'Neill AF, Bauer DE, Heeney MM, John K, Kuypers FA, Gallagher PG, Lux SE, Brugnara C, Westhoff CM, Alper SL. Loss-of-function and gain-of-function phenotypes of stomatocytosis mutant RhAG F65S. Am J Physiol Cell Physiol. 2011 Dec; 301(6):C1325-43.
  29. Sobota A, Graham DA, Neufeld EJ, Heeney MM. Thirty-day readmission rates following hospitalization for pediatric sickle cell crisis at freestanding children's hospitals: risk factors and hospital variation. Pediatr Blood Cancer. 2012 Jan; 58(1):61-5.
  30. Sobota A, Neufeld EJ, Sprinz P, Heeney MM. Transition from pediatric to adult care for sickle cell disease: results of a survey of pediatric providers. Am J Hematol. 2011 Jun; 86(6):512-5.
  31. Vichinsky E, Bernaudin F, Forni GL, Gardner R, Hassell K, Heeney MM, Inusa B, Kutlar A, Lane P, Mathias L, Porter J, Tebbi C, Wilson F, Griffel L, Deng W, Giannone V, Coates T. Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Br J Haematol. 2011 Aug; 154(3):387-97.
  32. Heeney MM. Rudolph’s Pediatrics. Iron Deficiency Anemia: Definition, Pathophysiology and Classification. 2011.
  33. Heeney MM. Rudolph’s Pediatrics (Rudolph AM, Rudolph C, First L, Lister G, Gershon AA. Editors). Anemia: Definition, Pathophysiology and Classification. 2011.
  34. Soranzo N, Sanna S, Wheeler E, Gieger C, Radke D, Dupuis J, Bouatia-Naji N, Langenberg C, Prokopenko I, Stolerman E, Sandhu MS, Heeney MM, Devaney JM, Reilly MP, Ricketts SL, Stewart AF, Voight BF, Willenborg C, Wright B, Altshuler D, Arking D, Balkau B, Barnes D, Boerwinkle E, Böhm B, Bonnefond A, Bonnycastle LL, Boomsma DI, Bornstein SR, Böttcher Y, Bumpstead S, Burnett-Miller MS, Campbell H, Cao A, Chambers J, Clark R, Collins FS, Coresh J, de Geus EJ, Dei M, Deloukas P, Döring A, Egan JM, Elosua R, Ferrucci L, Forouhi N, Fox CS, Franklin C, Franzosi MG, Gallina S, Goel A, Graessler J, Grallert H, Greinacher A, Hadley D, Hall A, Hamsten A, Hayward C, Heath S, Herder C, Homuth G, Hottenga JJ, Hunter-Merrill R, Illig T, Jackson AU, Jula A, Kleber M, Knouff CW, Kong A, Kooner J, Köttgen A, Kovacs P, Krohn K, Kühnel B, Kuusisto J, Laakso M, Lathrop M, Lecoeur C, Li M, Li M, Loos RJ, Luan J, Lyssenko V, Mägi R, Magnusson PK, Mälarstig A, Mangino M, Martínez-Larrad MT, März W, McArdle WL, McPherson R, Meisinger C, Meitinger T, Melander O, Mohlke KL, Mooser VE, Morken MA, Narisu N, Nathan DM, Nauck M, O'Donnell C, Oexle K, Olla N, Pankow JS, Payne F, Peden JF, Pedersen NL, Peltonen L, Perola M, Polasek O, Porcu E, Rader DJ, Rathmann W, Ripatti S, Rocheleau G, Roden M, Rudan I, Salomaa V, Saxena R, Schlessinger D, Schunkert H, Schwarz P, Seedorf U, Selvin E, Serrano-Ríos M, Shrader P, Silveira A, Siscovick D, Song K, Spector TD, Stefansson K, Steinthorsdottir V, Strachan DP, Strawbridge R, Stumvoll M, Surakka I, Swift AJ, Tanaka T, Teumer A, Thorleifsson G, Thorsteinsdottir U, Tönjes A, Usala G, Vitart V, Völzke H, Wallaschofski H, Waterworth DM, Watkins H, Wichmann HE, Wild SH, Willemsen G, Williams GH, Wilson JF, Winkelmann J, Wright AF, Zabena C, Zhao JH, Epstein SE, Erdmann J, Hakonarson HH, Kathiresan S, Khaw KT, Roberts R, Samani NJ, Fleming MD, Sladek R, Abecasis G, Boehnke M, Froguel P, Groop L, McCarthy MI, Kao WH, Florez JC, Uda M, Wareham NJ, Barroso I, Meigs JB. Common variants at 10 genomic loci influence hemoglobin A1(C) levels via glycemic and nonglycemic pathways. Diabetes. 2010 Dec; 59(12):3229-39.
  35. George M, Heeney MM, Woolf AD. Encephalopathy from lead poisoning masquerading as a flu-like syndrome in an autistic child. Pediatr Emerg Care. 2010 May; 26(5):370-3.
  36. Anderson DS, Heeney MM, Roth U, Menzel C, Fleming MD, Steen H. High-throughput matrix-assisted laser desorption ionization-time-of-flight mass spectrometry method for quantification of hepcidin in human urine. Anal Chem. 2010 Feb 15; 82(4):1551-5.
  37. Heeney MM, Ware RE. Hydroxyurea for children with sickle cell disease. Hematol Oncol Clin North Am. 2010 Feb; 24(1):199-214.
  38. Grace RF, Su H, Sena L, Poussaint TY, Heeney MM, Gutierrez A. Resolution of cerebral artery stenosis in a child with sickle cell anemia treated with hydroxyurea. Am J Hematol. 2010 Feb; 85(2):135-7.
  39. Ballas SK, Lieff S, Benjamin LJ, Dampier CD, Heeney MM, Hoppe C, Johnson CS, Rogers ZR, Smith-Whitley K, Wang WC, Telen MJ. Definitions of the phenotypic manifestations of sickle cell disease. Am J Hematol. 2010 Jan; 85(1):6-13.
  40. Sobota A, Graham DA, Heeney MM, Neufeld EJ. Corticosteroids for acute chest syndrome in children with sickle cell disease: variation in use and association with length of stay and readmission. Am J Hematol. 2010 Jan; 85(1):24-8.
  41. Smith ER, McClain CD, Heeney M, Scott RM. Pial synangiosis in patients with moyamoya syndrome and sickle cell anemia: perioperative management and surgical outcome. Neurosurg Focus. 2009 Apr; 26(4):E10.
  42. Morrissey LK, Shea JO, Kalish LA, Weiner DL, Branowicki P, Heeney MM. Clinical practice guideline improves the treatment of sickle cell disease vasoocclusive pain. Pediatr Blood Cancer. 2009 Mar; 52(3):369-72.
  43. Steinberg MH. Ohene-Frempong K. Heeney MM. Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management (Steinberg MH, Forget BG, Higgs DR, Weatherall DJ. Editors). Clinical and Pathophysiological Aspects of Sickle Cell Anemia. 2009; 437-496.
  44. Hettmer S, Heeney MM. Cefepime-induced neutropenia in a teenager. Pediatr Blood Cancer. 2008 Nov; 51(5):715-6.
  45. Finberg KE, Heeney MM, Campagna DR, Aydinok Y, Pearson HA, Hartman KR, Mayo MM, Samuel SM, Strouse JJ, Markianos K, Andrews NC, Fleming MD. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet. 2008 May; 40(5):569-71.
  46. Heeney MM, Ware RE. Hydroxyurea for children with sickle cell disease. Pediatr Clin North Am. 2008 Apr; 55(2):483-501, x.
  47. Aygun B, McMurray MA, Schultz WH, Kwiatkowski JL, Hilliard L, Alvarez O, Heeney M, Kalinyak K, Lee MT, Miller S, Helms RW, Ware RE. Chronic transfusion practice for children with sickle cell anaemia and stroke. Br J Haematol. 2009 May; 145(4):524-8.
  48. Dover GJ. Heeney MM. Nathan and Oski’s Hematology of Infancy and Childhood (Nathan DG, Orkin SH, Ginsburg D, Look AT. Editors). Sickle Cell Disease. 2008; 949-1014.
  49. Mazumdar M, Heeney MM, Sox CM, Lieu TA. Preventing stroke among children with sickle cell anemia: an analysis of strategies that involve transcranial Doppler testing and chronic transfusion. Pediatrics. 2007 Oct; 120(4):e1107-16.
  50. Tubman VN, Bennett CM, Luo HY, Chui DH, Heeney MM. Sickle cell disease caused by Hb S/Québec-CHORI: treatment with hydroxyurea and response. Pediatr Blood Cancer. 2007 Aug; 49(2):207-10.
  51. Masiello D, Heeney MM, Adewoye AH, Eung SH, Luo HY, Steinberg MH, Chui DH. Hemoglobin SE disease: a concise review. Am J Hematol. 2007 Jul; 82(7):643-9.
  52. Tubman VN, Smoot L, Heeney MM. Acquired immune cytopenias post-cardiac transplantation respond to rituximab. Pediatr Blood Cancer. 2007 Mar; 48(3):339-44.
  53. Heeney MM. Management of Sickle Cell Disease,. Comprehensive Pediatric Hospital Medicine (Zaoutis LD, Chiang VW). 2007; 731-737.
  54. Duncan C. Heeney MM. Hematologic Disorders. Manual of Pediatric Therapeutics (Greenes DS, Graeff JW.). 2007; 466-499.
  55. Luo HY, Heeney M, Wang WC, Eung SH, Ware RE, Steinberg MH, Chui DH. Hemoglobinopathies mimicking Hb S/beta-thalassemia: Hb S/S with alpha-thalassemia and Hb S/Volga. Am J Hematol. 2006 May; 81(5):361-5.
  56. Heeney MM. Risk of cholelithiasis in sickle cell anemia. Haematologica. 2005 Feb; 90(2):147.
  57. Heeney MM, Andrews NC. Iron homeostasis and inherited iron overload disorders: an overview. Hematol Oncol Clin North Am. 2004 Dec; 18(6):1379-403, ix.
  58. Heeney MM, Whorton MR, Howard TA, Johnson CA, Ware RE. Chemical and functional analysis of hydroxyurea oral solutions. J Pediatr Hematol Oncol. 2004 Mar; 26(3):179-84.
  59. Heeney MM, Zimmerman SA, Ware RE. Childhood autoimmune cytopenia secondary to unsuspected common variable immunodeficiency. J Pediatr. 2003 Nov; 143(5):662-5.
  60. Heeney MM, Ormsbee SM, Moody MA, Howard TA, DeCastro CM, Ware RE. Increased expression of anti-apoptosis genes in peripheral blood cells from patients with paroxysmal nocturnal hemoglobinuria. Mol Genet Metab. 2003 Apr; 78(4):291-4.
  61. Heeney MM, Howard TA, Zimmerman SA, Ware RE. UGT1A promoter polymorphisms influence bilirubin response to hydroxyurea therapy in sickle cell anemia. J Lab Clin Med. 2003 Apr; 141(4):279-82.
  62. Heeney MM. Ware RE. Diagnostic Approach to Sickle Hemoglobinopathies. Practical Algorithms in Pediatric Hematology-Oncology (Sills R). 2003.
  63. Ware RE. Heeney MM. Pickens CV. DeCastro CM. Howard TA. A multi-step model for the pathogenesis and evolution of PNH. Paroxysmal Nocturnal Hemoglobinuria (PNH) and Related Disorders. 2003; 41-54.
  64. Heeney MM. Ware RE. . Newborn Screening for Hemoglobinopathies. Practical Algorithms in Pediatric Hematology Oncology (Sills R.). 2003.
  65. Heeney MM, Delgrosso K, Robinson R, Johnson CA, Daeschner CW, Campbell TA, Surrey S, Ware RE. Interpretation of fetal hemoglobin only on newborn screening for hemoglobinopathy. J Pediatr Hematol Oncol. 2002 Aug-Sep; 24(6):499-502.
  66. Zhang XL, Seong R, Piracha R, Larijani M, Heeney M, Parnes JR, Chamberlain JW. Distinct stage-specific cis-active transcriptional mechanisms control expression of T cell coreceptor CD8 alpha at double- and single-positive stages of thymic development. J Immunol. 1998 Sep 1; 161(5):2254-66.
  67. Kushida MM, Dey A, Zhang XL, Campbell J, Heeney M, Carlyle J, Ganguly S, Ozato K, Vasavada H, Chamberlain JW. A 150-base pair 5' region of the MHC class I HLA-B7 gene is sufficient to direct tissue-specific expression and locus control region activity: the alpha site determines efficient expression and in vivo occupancy at multiple cis-active sites throughout this region. J Immunol. 1997 Nov 15; 159(10):4913-29.
  68. "Retrospective Assessment of Utilisation and Effect on Management of Echocardiography in Patients with Suspected Mitral Valve Prolapse" . Supervisor: D. Isaac, MD Year II Research Elective, Faculty of Medicine, University of Calgary, Calgary, AB . 1996.
  69. "The Mechanisms of Scaphoid Fracture and Relation to Hand of Dominance, Activity During Injury, and Anatomical Site of Fracture: A Retrospective Analysis" . Year I Research Elective, Faculty of Medicine, University of Calgary, Calgary, AB. 1995.
  70. "Distinct Regulatory Mechanisms Control CD8 Expression in CD4+/CD8+ Thymocytes vs. CD4-/CD8- in vivo". Oral Presentation, Hospital for Sick Children Research Institute, Toronto, ON. 1992.
  71. "Renal Expression of Urokinase-type Plasminogen Activator is Decreased in Experimental Nephrosis.". Oral Presentation, Hospital for Sick Children Research Institute, Toronto, ON. 1991.
To schedule an appointment: Call 617-355-7700 or Request an Appointment

Locations

We are grateful to have been ranked #1 on U.S. News & World Report's list of the best children's hospitals in the nation for the third year in a row, an honor we could not have achieved without the patients and families who inspire us to do our very best for them. Thanks to you, Boston Children's is a place where we can write the greatest children's stories ever told.”
- Sandra L. Fenwick, President and CEO

Boston Children's Hospital 300 Longwood Avenue, Boston, MA 02115 617-355-6000 | 800-355-7944

Close